Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RANK ligand and the regulation of skeletal remodeling.

× No keyword cloud information.

24 in total

Review 1. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors: S C Manolagas
Journal: Endocr Rev Date: 2000-04 Impact factor: 19.871

Review 2. Therapeutic approaches to bone diseases.

Authors: G A Rodan; T J Martin
Journal: Science Date: 2000-09-01 Impact factor: 47.728

Review 3. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors: L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal: J Bone Miner Res Date: 2000-01 Impact factor: 6.741

4. The effect of a single dose of osteoprotegerin in postmenopausal women.

Authors: P J Bekker; D Holloway; A Nakanishi; M Arrighi; P T Leese; C R Dunstan
Journal: J Bone Miner Res Date: 2001-02 Impact factor: 6.741

Review 5. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Authors: T Suda; N Takahashi; N Udagawa; E Jimi; M T Gillespie; T J Martin
Journal: Endocr Rev Date: 1999-06 Impact factor: 19.871

6. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.

Authors: K Thirunavukkarasu; R R Miles; D L Halladay; X Yang; R J Galvin; S Chandrasekhar; T J Martin; J E Onyia
Journal: J Biol Chem Date: 2001-07-12 Impact factor: 5.157

7. B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta.

Authors: M N Weitzmann; S Cenci; J Haug; C Brown; J DiPersio; R Pacifici
Journal: J Cell Biochem Date: 2000-05 Impact factor: 4.429

8. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation.

Authors: S Srivastava; G Toraldo; M N Weitzmann; S Cenci; F P Ross; R Pacifici
Journal: J Biol Chem Date: 2000-12-19 Impact factor: 5.157

9. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.

Authors: T Mashiba; C H Turner; T Hirano; M R Forwood; C C Johnston; D B Burr
Journal: Bone Date: 2001-05 Impact factor: 4.398

10. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Authors: H Min; S Morony; I Sarosi; C R Dunstan; C Capparelli; S Scully; G Van; S Kaufman; P J Kostenuik; D L Lacey; W J Boyle; W S Simonet
Journal: J Exp Med Date: 2000-08-21 Impact factor: 14.307

10 in total

1. OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell.

Authors: Jian Chen; Jian-Quan He; Shu-Yu Zhen; Li-Qun Huang
Journal: Rheumatol Int Date: 2011-12-31 Impact factor: 2.631

Review 2. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.

Authors: Erik R Nelson; Suzanne E Wardell; Donald P McDonnell
Journal: Bone Date: 2012-11-17 Impact factor: 4.398

3. Is a gene important for bone resorption a candidate for obesity? An association and linkage study on the RANK (receptor activator of nuclear factor-kappaB) gene in a large Caucasian sample.

Authors: Lan-Juan Zhao; Yan-Fang Guo; Dong-Hai Xiong; Peng Xiao; Robert R Recker; Hong-Wen Deng
Journal: Hum Genet Date: 2006-09-08 Impact factor: 4.132

4. The G-protein-coupled receptor GPR103 regulates bone formation.

Authors: Helene Baribault; Jean Danao; Jamila Gupte; Li Yang; Banghua Sun; William Richards; Hui Tian
Journal: Mol Cell Biol Date: 2006-01 Impact factor: 4.272

5. In vivo genome-wide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis.

Authors: Peng Xiao; Yuan Chen; Hui Jiang; Yao-Zhong Liu; Feng Pan; Tie-Lin Yang; Zi-Hui Tang; Jennifer A Larsen; Joan M Lappe; Robert R Recker; Hong-Wen Deng
Journal: J Bone Miner Res Date: 2008-05 Impact factor: 6.741

6. Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model.

Authors: L Zhang; T-H Jia; A C M Chong; L Bai; H Yu; W Gong; P H Wooley; S-Y Yang
Journal: Gene Ther Date: 2010-04-29 Impact factor: 5.250

7. Attenuated monocyte apoptosis, a new mechanism for osteoporosis suggested by a transcriptome-wide expression study of monocytes.

Authors: Yao-Zhong Liu; Yu Zhou; Lei Zhang; Jian Li; Qing Tian; Ji-Gang Zhang; Hong-Wen Deng
Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240

8. Accelerated and increased joint damage in young mice with global inactivation of mitogen-inducible gene 6 after ligament and meniscus injury.

Authors: Danese M Joiner; Kennen D Less; Emily M Van Wieren; Yu-Wen Zhang; Daniel Hess; Bart O Williams
Journal: Arthritis Res Ther Date: 2014-03-27 Impact factor: 5.156

9. The role of osteocytes in targeted bone remodeling: a mathematical model.

Authors: Jason M Graham; Bruce P Ayati; Sarah A Holstein; James A Martin
Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240

10. Therapeutic potentials of naringin on polymethylmethacrylate induced osteoclastogenesis and osteolysis, in vitro and in vivo assessments.

Authors: Nianhu Li; Zhanwang Xu; Paul H Wooley; Jianxin Zhang; Shang-You Yang
Journal: Drug Des Devel Ther Date: 2013-12-10 Impact factor: 4.162

10 in total